Why the study?
Does nifekalant hydrochloride safely suppress refractory ventricular tachyarrhythmia without compromising hemodynamics in patients with acute extensive infarction and severe ventricular dysfunction?
Does nifekalant hydrochloride safely suppress refractory ventricular tachyarrhythmia without compromising hemodynamics in patients with acute extensive infarction and severe ventricular dysfunction?
Low-dose intravenous nifekalant effectively suppressed refractory ventricular tachyarrhythmias in patients with acute myocardial infarction and severe LV dysfunction without causing hemodynamic compromise.
May support nifekalant for refractory VT in acute MI with severe LV dysfunction; hypothesis-generating, needs prospective validation.
Nifekalant hydrocholoride, a novel class III antiarrhythmic agent, was used as the treatment in 4 patients with extensive anterior infarction and severe ventricular dysfunction. The malignant ventricular tachyarrhythmia was effectively suppressed at a relatively low dose, without compromising the hemodynamics, indicating that this potent K+ channel blocker has therapeutic potential for acute myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Takenaka et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: